Development and validation of the ASGARD-S risk score for optimal timing of echocardiograms in asymptomatic patients with non-severe aortic valve stenosis: the SEAS and SALTIRE II trials

30 August 2024 (08:00 - 17:30)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Doctor Edina Hadziselimovic

Bispebjerg University Hospital, Copenhagen (Denmark)

7 More presentations in this session

Presentation thumbnail

Effect of Aficamten on Cardiac Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM CMR Trial

Doctor A. Masri (Portland, US)

Presentation thumbnail

Effect of Aficamten on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM

Doctor J. Spertus (Kansas City, US)

Presentation thumbnail

Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Doctor S. Hegde (Dallas, US)

Presentation thumbnail

Safety and Outcomes of Standard of Care Medications Withdrawal in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in FOREST-HCM Trial

Doctor A. Masri (Portland, US)

Presentation thumbnail

Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis

Associate Professor M. Banovic (Belgrade, RS)

Access the full session

Session thumbnail

Trial updates and other studies in hypertrophic cardiomyopathy and aortic stenosis

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

You may be interested in

Webinar

Risk assessment and lipid management in primary prevention

Congress Presentation

Cardiovascular prevention in older adults

Congress Presentation

Making personalised prevention everyone's business

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources